Korro Bio, Inc. Stock Price, News & Analysis

Korro Bio (NASDAQ:KRRO) reported Q2 2025 financial results and provided significant pipeline updates. The company has made substantial progress in its Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), with over 80% of planned healthy volunteers dosed and no serious adverse events observed. The company received EMA Orphan Drug Designation for KRRO-110.

Financially, Korro ended Q2 with $119.6 million in cash, reporting a net loss of $25.8 million. R&D expenses increased to $21.0 million, while collaboration revenue with Novo Nordisk reached $1.5 million. The company's current cash position is expected to fund operations into 2027.

Key upcoming milestones include an interim readout from the REWRITE trial in H2 2025, trial completion in 2026, and announcement of a new development candidate for a rare metabolic disorder by end of 2025.

Korro Bio (Nasdaq: KRRO) has received orphan drug designation from the European Medicines Agency (EMA) for KRRO-110, its investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD). This follows the FDA's orphan drug designation granted in March 2025.

KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study, with an interim readout expected in H2 2025. The EMA designation provides significant benefits, including protocol assistance, reduced fees, and market exclusivity upon approval, and is granted to medicines treating conditions affecting fewer than 5 in 10,000 people in the EU.

Korro Bio (NASDAQ: KRRO) has announced its management team's participation in three major upcoming healthcare investor conferences in May and June 2025. CEO and President Ram Aiyar, Ph.D., will lead a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21. Both Dr. Aiyar and Chief Medical Officer Kemi Olugemo, M.D., FAAN, will present at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9.

The RBC fireside chat will be available via webcast on Korro's website, with a replay accessible for 30 days following the event.

Korro Bio (NASDAQ: KRRO) reported its Q1 2025 financial results and provided key business updates. The company announced a 20% workforce reduction and operational streamlining to extend cash runway into 2027, with expected one-time restructuring charges of $1.2 million. The company ended Q1 with $139.0 million in cash.

Key financial metrics include $2.6 million in collaboration revenue, R&D expenses of $19.7 million (up from $13.6M), and a net loss of $23.4 million. The company strengthened its leadership team with appointments of Loïc Vincent as CSO and GaoZhong Zhu as SVP of CMC.

Korro remains on track for an interim readout from Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency in H2 2025, with trial completion expected in 2026. The company continues executing its 3-2-1 strategy through 2027 and plans to announce a second development candidate in 2025.

Korro Bio (NASDAQ: KRRO), a clinical-stage biopharmaceutical company developing RNA-editing genetic medicines, has announced key leadership appointments. Loïc Vincent, Ph.D. joins as Chief Scientific Officer, bringing over 20 years of drug discovery experience and a track record of advancing more than 20 drugs into clinical development.

The company also appointed GaoZhong Zhu, Ph.D. as Senior Vice President of CMC & Technical Operations, leveraging his 25+ years of pharmaceutical development experience. Additionally, Oliver Dolan was promoted to Principal Accounting Officer.

Korro is currently conducting the Phase 1/2a REWRITE clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. The company's RNA-editing platform aims to develop treatments for both rare and highly prevalent diseases.

Korro Bio (NASDAQ: KRRO) has reported its full-year 2024 financial results and business updates. The company completed dosing of the first two single ascending dose cohorts in the Phase 1/2a REWRITE clinical study of KRRO-110 for AATD, with no serious adverse events observed. An interim readout is expected in H2 2025.

Financial highlights include: cash position of $163.1 million as of December 31, 2024, expected to fund operations into H2 2026; collaboration revenue of $2.3 million from Novo Nordisk partnership; R&D expenses increased to $63.6 million from $57.2 million in 2023; G&A expenses rose to $30.5 million from $27.3 million; net loss widened to $83.6 million from $81.2 million in 2023.

The company received Orphan Drug Designation for KRRO-110 and is executing its 3-2-1 strategy through 2027, aiming to establish three clinical-stage programs in two tissue types with a single RNA-editing platform. A second development candidate nomination is expected by end of 2025.

Korro Bio (Nasdaq: KRRO) announced that its investigational medicine KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110, the first RNA editing candidate from Korro's OPERA™ platform, is currently in Phase 1/2a REWRITE clinical study.

The company has completed dosing of the first two single ascending dose cohorts in healthy adult volunteers, with an interim readout expected in the second half of 2025. The orphan drug designation, granted for rare diseases affecting fewer than 200,000 people in the US, provides development incentives including tax credits, user fee exemptions, and potential market exclusivity post-FDA approval.

Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company specializing in RNA-based genetic medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The event will take place on March 4, 2025, at the Boston Marriott Copley Place.

CEO and President Ram Aiyar, Ph.D. will deliver a presentation at 11:50 a.m. ET, while COO Todd Chappell will engage in one-on-one investor meetings during the conference. Interested parties can access a live webcast of the presentation through Korro's website investor section, with a replay available for 30 days post-event.

Korro Bio has initiated dosing in the REWRITE Phase 1/2a study for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 aims to restore therapeutic M-AAT protein levels using the body's ADAR enzyme. The study will evaluate safety and tolerability in up to 64 participants, including healthy adults and AATD patients.

Interim data from Part 1 is expected in the second half of 2025, with study completion anticipated in 2026. The company is also advancing its pipeline, including a partnered program with Novo Nordisk in a cardiometabolic indication.

Korro's CEO, Ram Aiyar, highlighted the company's evolution to a clinical-stage organization and its strategy to take three product candidates into the clinic over the next three years. For more details, visit ClinicalTrials.gov (NCT06677307).